Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.
The U.S.
Supreme Court declined to hear an appeal from Eli Lilly & Co.
(NYSE:LLY), leaving in place a $194 million whistleblower judgment tied to allegations that the drugmaker underpaid Medicaid rebates by misreporting drug pricing data. • Eli Lilly stock is trending lower.
Why is LLY stock trading lower?
The Bloomberg report on Monday noted that the justices issued the decision without comment, rejecting Lilly's broader constitutional challenge to the federal False Claims Act.
Supreme Court rejects Big Pharma appeals challenging negotiated drug prices in Medicare | CNN Politics
Supreme Court rejects appeal from drugmakers over price negotiations - UPI.com
Supreme Court rejects challenge to Medicare drug price negotiation
The Supreme Court won't take up IRA cases
Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations
Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations with government
Supreme Court declines to hear IRA challenges from Novo, AZ and more
Takeda slapped with $885M verdict in pay-for-delay antitrust case
Pharma companies want to block Medicare drug discounts. Supreme Court weighs in
Takeda faces $885m hit after landmark pay-for-delay lawsuit verdict - Pharmaceutical Technology
